Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,177,972 papers from all fields of science
Search
Sign In
Create Free Account
BIIB021
Known as:
BIIB-021
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
HSP90 inhibitor CNF2024
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.
M. Dickson
,
S. Okuno
,
+5 authors
G. Schwartz
Annals of Oncology
2013
Corpus ID: 9220763
BACKGROUND HSP90 inhibition leads to proteosomal degradation of activated KIT and has in vitro activity against gastrointestinal…
Expand
2013
2013
A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
M. Saif
,
C. Takimoto
,
+6 authors
D. V. Von Hoff
Clinical Cancer Research
2013
Corpus ID: 26717830
Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin–based HSP90 inhibitor that showed activity in preclinical models…
Expand
2013
2013
A Purine Scaffold HSP90 Inhibitor BIIB021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K13-Induced NF-κB
R. Gopalakrishnan
,
H. Matta
,
P. Chaudhary
Clinical Cancer Research
2013
Corpus ID: 7514748
Purpose: Kaposi sarcoma–associated herpes virus (KSHV)–associated primary effusion lymphomas (PEL) have extremely poor prognosis…
Expand
Highly Cited
2009
Highly Cited
2009
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
K. Lundgren
,
Hong Zhang
,
+15 authors
F. Burrows
Molecular Cancer Therapeutics
2009
Corpus ID: 11703294
Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing…
Expand
Highly Cited
2009
Highly Cited
2009
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
R. Bao
,
Chengjung Lai
,
+13 authors
C. Qian
Clinical Cancer Research
2009
Corpus ID: 15641536
Purpose: We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique…
Expand
Highly Cited
2009
Highly Cited
2009
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy
Xiaoying Yin
,
Hong Zhang
,
K. Lundgren
,
L. Wilson
,
F. Burrows
,
C. Shores
International Journal of Cancer
2009
Corpus ID: 205939147
Heat shock protein 90 (Hsp90) is a molecular chaperone that promotes the conformational maturation of numerous client proteins…
Expand
Highly Cited
2009
Highly Cited
2009
BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
Hong Zhang
,
L. Neely
,
+4 authors
F. Burrows
International Journal of Cancer
2009
Corpus ID: 205939172
17‐AAG, the first‐generation clinical Hsp90 inhibitor, exhibits promising antitumor activity in clinical studies, but is limited…
Expand
2009
2009
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity
B. Böll
,
Farag Eltaib
,
+8 authors
E. Pogge von Strandmann
Clinical Cancer Research
2009
Corpus ID: 44592062
Purpose: In Hodgkin's lymphoma, constitutive activation of NF-κB promotes tumor cell survival and proliferation. The molecular…
Expand
Highly Cited
2009
Highly Cited
2009
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
N. Gaspar
,
S. Sharp
,
+6 authors
P. Workman
Cancer Research
2009
Corpus ID: 7258529
Heat shock protein 90 (HSP90) inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), which is…
Expand
2008
2008
BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
A. Elfiky
,
M. Saif
,
+7 authors
D. V. Hoff
2008
Corpus ID: 79439344
2503 Background: BIIB021 is an oral fully synthetic Hsp90 inhibitor that is being developed for both solid and hematologic tumors…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE